UNITED THERAPEUTICS Corp — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
United Therapeutics amended its wholesale product purchase agreement with Priority Healthcare Distribution (CuraScript SD) for Remodulin distribution, effective June 2026. The amendment replaced Exhibits A and B but specific commercial terms (pricing, volume, payment terms) are not disclosed in this filing excerpt. The agreement has been in place since January 1, 2018.
Why this rating
Routine contract amendment for existing product distribution. No dollar amounts, volume changes, or material commercial terms disclosed. Remodulin is a legacy product; amendment details unavailable.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.